Fulvestrant

Updated 
January 26, 2018
Reviewed By: 

Fulvestrantinfo-icon (Faslodexinfo-icon) is an estrogen receptorinfo-icon antagonistinfo-icon, or ERA, a class of medicineinfo-icon that stops the activity of estrogeninfo-icon on cancer cells to keep them from growing.

Who Gets Fulvestrant

Fulvestrantinfo-icon is FDAinfo-icon approved for use in postmenopausalinfo-icon women with metastaticinfo-icon hormone receptorinfo-icon-positive breast cancer. It may be given

  • to postmenopausal women, if the cancer is HER2-negative and they have not received hormonal therapyinfo-icon
  • to postmenopausal women, if the cancer grew while taking a different hormonal therapy
  • to anyone, with palbociclib (Ibrance) or abemaciclib (Verzenio) whose cancer grew despite treatment with a different hormonal therapy for early or metastatic breast cancer

How Fulvestrant Is Given

Fulvestrantinfo-icon is given by injectioninfo-icon into the buttocks. For the first month, you will receive two shots every 2 weeks. Afterward, it is given as two injections every 4 weeks.

Side Effects and Things to Remember

Common side effects of fulvestrant are:

You should not take fulvestrant if you are pregnant, and you should not become pregnant while taking it or for a year after treatment ends as fulvestrant can harm the fetus. You also should not breastfeed while taking fulvestrant.

You must have Javascript enabled to use this form.

More In Hormonal Therapy